Recursion Pharmaceuticals, Inc.
RXRX
$3.39
-$0.03-0.88%
NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -644.76M | -715.54M | -649.13M | -574.78M | -463.66M |
| Total Depreciation and Amortization | 83.70M | 77.17M | 63.33M | 48.45M | 36.49M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 175.56M | 196.91M | 176.45M | 153.66M | 114.75M |
| Change in Net Operating Assets | 13.69M | 296.00K | 26.33M | -16.16M | -46.76M |
| Cash from Operations | -371.81M | -441.17M | -383.03M | -388.83M | -359.17M |
| Capital Expenditure | -6.47M | -6.52M | -10.84M | -8.87M | -13.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 277.10M | 277.10M | 277.10M | 277.10M |
| Divestitures | -4.44M | -4.44M | -4.44M | -4.44M | -- |
| Other Investing Activities | -5.96M | -6.31M | -4.01M | -4.35M | -3.35M |
| Cash from Investing | -16.87M | 259.83M | 257.82M | 259.44M | 260.06M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.43M | -8.36M | -8.52M | -6.46M | -4.44M |
| Issuance of Common Stock | 532.96M | 411.52M | 176.81M | 337.21M | 308.56M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.00M | -3.00M | -3.00M | -- | -- |
| Cash from Financing | 521.53M | 400.17M | 165.29M | 330.75M | 304.12M |
| Foreign Exchange rate Adjustments | 18.04M | 12.49M | 11.02M | 1.65M | -3.41M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 150.90M | 231.31M | 51.09M | 203.01M | 201.60M |